Keyphrases
Multiple Sclerosis
100%
Interferon-α (IFN-α)
100%
Minocycline
100%
Efficacy Endpoint
50%
Placebo
50%
Adverse Events
25%
Relapsing-remitting multiple Sclerosis
25%
Brain Volume
12%
Randomized Placebo-controlled Trial
12%
Disease Control
12%
Beneficial Effects
12%
Magnetic Resonance Imaging Data
12%
Annualized Relapse Rate
12%
Magnetic Resonance Imaging
12%
Hazard Ratio
12%
Confidence Interval
12%
Twice Daily
12%
T2-weighted Imaging (T2WI)
12%
Medicine and Dentistry
Interferon
100%
Multiple Sclerosis
100%
Minocycline
100%
Placebo
62%
Magnetic Resonance Imaging
25%
Adverse Event
25%
Recurrence Risk
12%
Hazard Ratio
12%
Diseases
12%
Pharmacology, Toxicology and Pharmaceutical Science
Interferon
100%
Minocycline
100%
Multiple Sclerosis
100%
Placebo
62%
Adverse Event
25%
Diseases
12%
Recurrence Risk
12%